DUBLIN, Sept. 2, 2025 — Leads & Copy — Trinity Biotech plc (Nasdaq Global Select: TRIB) announced it has received written notice from Nasdaq confirming that it has regained compliance with the $1.00 per share minimum bid price requirement and the minimum market value of publicly held shares requirement.
Trinity Biotech had previously received notice from Nasdaq on March 14, 2025, that it was not in compliance with the minimum bid price requirement. On August 26, 2025, Nasdaq notified the company that it had regained compliance with the Minimum Bid Price Requirement, and the matter is now closed.
Also on March 14, 2025, the Company received notice from Nasdaq that the Company no longer met the requirement in Nasdaq Listing Rule 5450(b)(2)(C) that listed securities maintain a minimum market value of publicly held shares (MVPHS) of US $15,000,000. On August 29, 2025, the Company received a letter from Nasdaq notifying the Company that the Company had regained compliance with the MVPHS Requirement and the matter is now closed.
This release includes forward-looking statements. Trinity Biotech does not undertake any obligation to update any forward-looking statements.
Trinity Biotech is a commercial-stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors.
Contact:
Susan O’Connor
(353)-1-2769800
Source: Trinity Biotech
